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Abstract In this observational study, we analyzed the
long-term neuromuscular deficits of survivors of critical
illness. Intensive care unit-acquired muscular weakness
(ICU-AW) is a very common complication of critical
illness. Critical illness polyneuropathy (CIP) and critical
illness myopathy (CIM) are two main contributors to ICU-
AW. ICU-AW is associated with an increased mortality
and leads to rehabilitation problems. However, the long-
term outcome of ICU-AW and factors influencing it are not
well known. We analyzed the medical records of 490
survivors of critical illness, aged 18–75 years and located
in the area of the study center. Intensive care unit (ICU)
survivors with comorbidities that might influence neuro-
muscular follow-up examinations, muscle strength, or
results of nerve conduction studies, such as renal or hepatic
insufficiency, diabetes mellitus, or vitamin deficiency were
excluded. A total of 51 patients were finally included in the
study. Six to 24 months after discharge from the ICU, we
measured the Medical Research Council (MRC) sum score,
the Overall Disability Sum score (ODSS), and also
performed nerve conduction studies and EMG. For all ICU
survivors, the median MRC sum score was 60 (range
47–60) and the median ODSS score was 0 (range 0–8). CIP
was diagnosed in 21 patients (41 %). No patient was
diagnosed with CIM. Patients with diagnosis of CIP
showed a higher median ODSS scores 1 (range 0–8) versus
0 (range 0–5); p \ 0.001 and lower median MRC sum
scores 56 (range 47–60) versus 60 (range 58–60);
p \ 0.001. The three main outcome variables MRC sum
score, ODSS score and diagnosis of CIP were not related to
age, gender, or diagnosis of sepsis. The MRC sum score
(r = -0.33; p = 0.02) and the ODSS score (r = 0.31;
p = 0.029) were correlated with the APACHE score. There
was a trend for an increased APACHE score in patients
with diagnosis of CIP 19 (range 6–33) versus 16.5 (range
6–28); p = 0.065. Patients with the diagnosis of CIP had
more days of ICU treatment 11 days (range 2–74) versus
4 days (range 1–61); p = 0.015, and had more days of
ventilator support 8 days (range 1–59) versus 2 days (range
1–46); p = 0.006. The MRC sum score and the ODSS
score were correlated with the days of ICU treatment and
with the days of ventilator support. The neuromuscular
long-term consequences of critical illness were not severe
in our study population. As patients with concomitant
diseases and old patients were excluded from this study the
result of an overall favorable prognosis of ICU-acquired
weakness may not be true for other patient’s case-mix. Risk
factors for the development of long-term critical illness
neuropathy are duration of ICU treatment, duration of
ventilator support, and a high APACHE score, but not
diagnosis of sepsis. Although ICU-AW can be serious
complication of ICU treatment, this should not influence
therapeutic decisions, given its favorable long-term prog-
nosis, at least in relatively young patients with no con-
comitant diseases.
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Introduction
Intensive care unit-acquired muscular weakness (ICU-
AW), as the consequence of critical illness polyneuropathy
(CIP) or critical illness myopathy (CIM), is recognized as a
common cause of muscular weakness, occurring in at least
50 % of critical ill patients [12]. In the majority of patients,
a combination of both CIP and CIM is diagnosed [12].
Depending on the patient population, a prevalence of ICU-
AW of up to 100 % of critical ill patients is described, with
sepsis or systemic inflammatory response syndrome (SIRS)
as one of the most important risk factors [1–3, 15, 21].
ICU-AW is a common cause of failure of weaning from
ventilation, and substantially contributes to mortality and
rehabilitation problems [3, 6, 17].
As important as the cause and frequency of muscular
weakness during and immediately after the intensive care
unit (ICU) treatment is the association with adverse long-
term outcomes. In a systematic review about the long-term
outcome of ICU-AW, 28 % of patients had severe disability
(quadriparesis/paraparesis), with a mean duration of follow-
up for 3–6 months [16], and even in patients with functional
recovery varying degrees of electrophysiological abnor-
malities after a median of 43 months have been observed [5].
However, often these studies include only a limited number
of patients or investigate within a limited follow-up period.
In this observational study, we describe the neuromus-
cular long-term consequences of critical illness in a group
of 51 survivors of critical illness, 6–24 months after dis-
charge from the ICU.
Methods
Patient selection
Medical records of ICU survivors treated in one of the ICU
at the University of Bonn or of the Helios Clinic in Sieg-
burg, Germany, between January 2004 and August 2006,
aged between 18 and 75 years, and lived in the area (= not
more than 50 km away from the hospital) were examined
(n = 490). Those who met the inclusion/exclusion criteria
given below were contacted by mailed letter and invited to
participate in the study.
Main inclusion criterion comprised history of ICU
treatment due to sepsis or systemic inflammatory response
syndrome (SIRS) according to the diagnostic criteria
defined by the American College of Chest Physicians/
Society of Critical Care Medicine Consensus Conference
[18], acute respiratory distress syndrome, polytrauma,
cardiac arrhythmia, or coronary heart disease. There was
no pre-specified minimum duration of ICU stay or
mechanical ventilation. We excluded patients with cancer
and patients with cerebral or spinal lesions such as head or
spinal trauma or stroke because we wanted to avoid con-
founders of neuromuscular performance that are not
directly linked with the ICU treatment. We further exclu-
ded patients with pre-existing neuromuscular dysfunction,
or diseases that might influence neuromuscular function,
muscle strength or results of nerve conduction studies, such
as renal or hepatic insufficiency, diabetes mellitus, vitamin
deficiency, or alcohol abuse. No patient included in this
study was treated with steroids other than hydrocortisone in
some cases of adrenal insufficiency. No patient was treated
with neuromuscular blocking agents during ICU treatment.
Medical data collected during ICU treatment included
diagnosis, length of ICU stay, APACHE II scores, car-
diovascular data, and duration of ventilation support.
The ICU treatment of all patients was carried out
according to standard clinical procedures. All patients gave
a self-report of considerable muscular weakness at the time
of ICU and hospital discharge. Muscular disability at ICU
discharge ranged from the inability to walk [100 m
without a rest to being completely bedridden. All ICU
patients were discharged to a rehabilitation clinic. The
length of the rehabilitation program was determined by the
rehabilitation clinic. No patient received an inpatient
rehabilitation program at the time of the follow-up exam-
ination. Four (=8 %) received ambulatory physiotherapy.
Study design
This study was carried out within a time period of
6–24 months after discharge from the ICU. All patients
underwent diagnostic laboratory tests to exclude laboratory
anomalies that could potentially influence study results.
Laboratory tests performed were blood cell count, liver
enzymes [serum aspartate (AST), alanine aminotransferase
(ALT), gamma-glutamyl transferase (GGT)], creatinine
levels, blood coagulation parameters (PTT, INR), vitamin
B12 and folic acid levels, c-reactive protein, creatine
kinase, electrolytes, immunofixation, thyroid function
(TSH levels, additional free T3 and T4 levels if TSH levels
were abnormal), HbA1c, and hepatitis B, C, and HIV
antigen levels). AST, ALT, and GGT were considered
abnormal if they showed an increase of more than twofold
of the standard value. For all other laboratory tests, the
normal standard values were used. Patients with laboratory
abnormalities were excluded from the study. We excluded
patients who had renal or hepatic insufficiency before or
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after their ICU stay. Patients who developed renal or
hepatic insufficiency only during their ICU stay were not
excluded.
Outcome measures included a neurological examination
and nerve conductions studies. Neurological examination
was carried out by a neurologist. Clinical findings were
graded with the Medical Research Council (MRC) sum
score and the Overall Disability Sum score (ODSS). The
MRC sum score is a summation of MRC grades (range
0–5) given in full numbers of the following muscle pairs:
upper arm abductor, elbow flexors, wrist extensors, hip
flexors, knee extensors, and foot dorsal flexors. The MRC
sum score ranges from 0 (complete plegia) to 60 (normal
muscle strength in all examined muscles). Good validity
and interobserver reliability for the MRC sum score has
been demonstrated in patients with Guillain–Barre´ syn-
drome [13]. The ODSS is composed of an arm and leg
disability scale with a total score ranging from 0 (no signs)
to 12 (severe disability). The ODSS gives a description of
arm and leg function in daily activities in a checklist form,
such as dressing, doing and undoing buttons, or walking.
The ODSS has shown good validity and reliability in
immune mediated polyneuropathies [19].
Nerve conduction studies were carried out by one
experienced neurophysiologist using a Nicolet system
(Viasis Healthcare, Nicvue 2.6.8) and record techniques
according to the American Association of Electrodiagnos-
tic Medicine. Motor studies were performed in the median,
ulnar, common peroneal, and tibial nerves (one each).
Sensory action potentials were recorded from the median,
ulnar, and sural nerve (one each). For motor nerve con-
duction studies, the active electrode was placed over the
muscle belly and the reference over an electrically inactive
site (usually bony prominence). A ground electrode was
placed between the stimulating and recording electrodes.
The filter settings were a low-pass filter 30 Hz and a high-
pass filter of 100 kHz. Median nerve: recorded from
abductor pollicis brevis muscle, distal stimulation at the
wrist, proximal stimulation below the elbow in the ante-
cubital fossa. Ulnar nerve: recorded from the abductor
digiti minimi muscle, distal stimulation at the wrist,
proximal stimulation below and above the elbow near the
sulcus ulnaris. Tibial nerve: recorded from the abductor
hallucis muscle, distal stimulation posterior to the medial
malleolus, proximal stimulation in the popliteal fossa.
Peroneal nerve: recorded from the extensor digitorum
brevis muscle, distal stimulation at the ankle, proximal
stimulation distal and proximal of the fibula head. For
sensory nerve conduction studies, the sensory nerve action
potential (SNAP) was recorded orthodromically. Filter
settings were 10-Hz low-pass filter and 10-kHz high-pass
filter. Median and ulnar nerve: stimulation with ring elec-
trodes on the index finger or fifth finger, recording with
surface electrodes over the nerve below the wrist. Sural
nerve: stimulation posterior of the lateral malleolus,
recording from distal of the ending of the gastrocnemius
muscle at the junction of the middle and lower third of the
leg. When a co-existence of CIP and CIM could not be
reliably excluded after clinical examination and nerve
conduction studies (n = 5), an additional EMG was per-
formed with a standard concentric needle electrode inserted
in the muscle that showed the most severe weakness
(Tibialis anterior muscle, Vastus lateralis muscle).
The parameters included in the motor nerve conduction
studies were distal latency, conduction velocity, distal
compound muscle action potential (CMAP) amplitude,
conduction block (\30 % drop in proximal CMAP to
distal), and minimal F-wave latency. In sensory nerve
conduction, nerve conduction velocity and sensory nerve
action potential (SNAP) amplitude were measured. For
defining abnormality, our age-adjusted laboratory control
values were used. Limbs were warmed with heat packs if
necessary. EMG was analyzed for spontaneous activity at
complete rest and motor unit action potential (MUAP)
waveform during minimal voluntary contraction.
Criteria for the diagnosis of CIP were (1) the presence of
clinical signs typical for distal symmetric polyneuropathy
such as symmetric weakness and/or atrophy of muscles
most prominent distally and in the legs, and absent or
diminished deep tendon reflexes most prominent in the
ankle reflexes, and symmetric impaired sensation most
prominent distally and in the legs; (2) Nerve conduction
studies showed signs typical for distal symmetric poly-
neuropathy; minimum criterion was an abnormality in two
separate nerves, one of which must be the sural nerve or in
three different nerves [4].
Criteria for CIM were (1) the presence of clinical signs
typical for myopathy such as symmetric, maximal proxi-
mally weakness and/or atrophy of muscles and no impaired
sensation; (2) Nerve conduction studies suggestive of
myopathy, which is reduced CMAPs, normal or only
minimally reduced motor nerve conduction velocity, no
abnormalities in sensory nerve conduction studies; (3)
EMG with reduced length and amplitude of motor unit
action potential (MUAP) waveform during minimal vol-
untary contraction.
Data and scores are presented as median (range) and
were compared between groups using the Mann–Whitney
test. Spearman rank analysis was used to calculate corre-
lations of age, days of ICU stay, days with ventilator
support, and APACHE II scores with the outcome variables
MRC sum scale and ODSS score as a dependent variable.
Binary variables (gender, diagnosis of sepsis, and diagnosis
of CIP/CIM) were compared using Fisher’s exact test. To
further analyze whether duration of ventilator support is a
risk factor independent from the diagnosis of sepsis, we
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performed a multiple logistic regression with diagnosis of
CIP as a dependent variable and duration of ventilator
support and diagnosis of sepsis as independent variables.
Because of its skew distribution, duration of ventilator
support was log-transformed for this analysis. The program
IBM SPSS Statistics version 19 (SPSS Inc., Chicago, IL,
USA) was used for statistical analyses. Two-tailed p values
\0.05 are considered statistically significant. All patients
gave written informed consent to the study. The study was
approved by the local ethical committee.
Results
For this study, the medical records of 490 survivors of
critical illness were analyzed and 102 patients were exclu-
ded because they did not meet the exclusion/inclusion cri-
teria. Of these 102 patients, 27 were excluded due to a
neurologic disease that could possibly impair neuromus-
cular function including head and spinal trauma, stroke, and
pre-existing polyneuropathy. Eleven were excluded due to a
diagnosis of cancer, 29 because they were diagnosed with
diabetes, 15 due to a diagnosis of renal impairment, 13 due
to diagnosis of alcohol abuse, and 7 were diagnosed with
chronic viral infection (hepatitis B/C, HIV).
The remaining 388 ICU survivors were invited to par-
ticipate in the study. There were 327 ICU survivors that did
not answer the invitation or refused to participate, so that
61 survivors (response rate 15.7 %) came to the hospital
for the follow-up examination. Ten were excluded because
of laboratory abnormalities or because they refused to
participate in nerve conduction studies, and in the end, 51
ICU survivors could be included in the study (Fig. 1).
Demographic and clinical characteristics
All data are presented as median (range). The median time
from intensive care unit discharge to follow-up was
11 months (range 6–24). The median age of the patients
was 57 years (range 19–75) (female 47 %). Twenty-four
patients (47 %) were diagnosed with severe sepsis or septic
shock during ICU treatment. Seven (14 %) had coronary
artery bypass surgery because of coronary artery heart
disease or cardiac arrhythmia, six (12 %) were diagnosed
with acute respiratory distress syndrome, 14 (27 %) were
trauma patients. Median length of ICU treatment was
5 days (range 1–74). Median length of ventilator support
was 3 days (range 1–59), median APACHE II score was 17
(range 3–33). Sepsis survivors did not differ from non-
septic ICU survivors in age or gender. Sepsis survivors
stayed longer on the ICU (13 days (range 3–74) versus
3 days (range 1–12); p \ 0.001, showed a higher APACHE
II Score of 20 (range 8–33) versus 14.5 (range 6–22);
p \ 0.001, and more days with ventilator support 10.5
(range 1–59) versus 1 (range 1–9); p \ 0.001.
Neuromuscular scores and results of nerve conduction
studies
For all ICU survivors, the MRC sum score was 60 (range
47–60) and the ODSS score was 0 (range 0–8). CIP was
diagnosed in 21 patients (41 %). Please see Table 1 for
details of nerve conduction studies. Patients with diagnosis
of CIP showed a higher ODSS scores 1 (range 0–8) versus
0 (range 0–5); p \ 0.001 and lower MRC sum scores 56
(range 47–60) versus 60 (range 58–60); p \ 0.001. All
patients with an MRC score\58 were diagnosed with CIP.
All patients diagnosed with CIP had abnormalities in motor
and sensory nerve conduction. No patient had reduced
CMAPs as the exclusive abnormality in nerve conduction,
indicative of myopathy (= CIM). If the co-existence of CIP
and CIM could not be excluded on the basis of the clinical
examination and nerve conduction studies, we additionally
performed EMG (n = 5). All EMGs showed neurogenic
changes. Therefore, no patient was diagnosed with CIM or
co-existing CIM/CIP.
The three main outcome variables (MRC sum score,
ODSS score, and diagnosis of CIP) were not related to age,
gender, diagnosis of sepsis, or time from ICU discharge to
follow-up. The MRC sum score and the ODSS score was
correlated with the APACHE score. There was a trend for
an increased APACHE score in patients with diagnosis of
CIP 19 (range 6–33) versus 16.5 (range 6–28); p = 0.065.
Patients with the diagnosis of CIP had more days of ICU
treatment 11 days (range 2–74) versus 4 days (range
490 ICU survivors 
identified
388 ICU survivors 
invited
61 came for follow-
up examination
51 ICU survivors     
included   
102 did not meet 
exclusion/inclusion criteria
327 did not answer/refused
study participation 
10 laboratory abnormalities, 
refused nerve conduction 
studies
24 survivors of 
sepsis/SIRS included   
27 non-septic ICU 
survivors included   
Fig. 1 Summary of patient recruitment
154 J Neurol (2013) 260:151–157
123
1–61); p = 0.015, and had more days of ventilator support
8 days (range 1–59) versus 2 days (range 1–46);
p = 0.006. The MRC sum score and the ODSS score were
correlated with the days of ICU treatment and with the days
of ventilator support (Table 2).
As mentioned above, the diagnosis of sepsis is associ-
ated with a longer duration of ventilator support. Logistic
regression with the diagnosis of CIP as a dependent vari-
able and duration of ventilator support (log-transformed)
and the diagnosis of sepsis as independent variables
showed that duration of ventilator support is an indepen-
dent risk factor for diagnosis of CIP (OR 2.3, 95 % CI
1.3–4.2, p = 0.004 with each doubling of the duration of
ventilator support), while sepsis is no independent risk
factor (p = 0.10) as it was in the univariate analysis.
Discussion
In our study population, the neuromuscular long-term
consequences of critical illness were not severe, sug-
gesting a favorable prognosis of ICU-acquired muscular
weakness. Other authors described a less favorable out-
come with around 10–25 % of ICU survivors suffering
from sustained and severe neuromuscular disability
ranging from reduced 6-min walking distance up to
tetraplegia [8–10, 14]. The difference between these
studies and the current one might be explained by patient
selection. For this study, patients with diseases that might
influence neuromuscular function were carefully exclu-
ded. Also, the average age of 56 years in the study
population was relatively low, and speculatively, elderly
ICU survivors experience more long-term neuromuscular
deficits. Another reason for the good neuromuscular out-
come may be the minimal use of neuromuscular blocking
agents and steroids in our study population, as this has
been described to be a risk factor for CIM and CIP by
several authors [14]. In addition to this, early rehabilita-
tion in the ICU or immediately thereafter improves the
functional recovery and independence [14] and this has
been applied in all our patients. It is possible that there
was some selection bias in that patients who saw them-
selves as unable to return to the hospital for the follow-up
examination may have been more severely disabled than
those who agreed to participate. Unfortunately, we do not
have any means to estimate the degree of this potential
selection bias. Therefore, the conclusion of a favorable
outcome of ICU-acquired weakness might only apply to
healthy and younger ICU survivors, and may not be true
for other patients’ case-mix. On the other hand, this study
shows that under optimal conditions (complete resolution
of the underlying disease, no relevant concomitant
Table 1 Percentages for a
normal/abnormal/unrecordable
result of nerve conduction
studies for all patients (n = 51)
and every nerve examined
DL distal latency, CMAP
compound muscle action
potential, SNAP sensory nerve
action potential, CV conduction
velocity
Nerve DL CMAP/SNAP CV F-wave latency
Median (motor) 82/16/2 88/10/2 84/14/2 80/18/2
Median (sensory) – 84/16/0 77/23/0 –
Ulnar (motor) 92/2/0 90/10/0 94/6/0 –
Ulnar (sensory) – 80/18/2 82/16/2 –
Peroneal 84/10/6 53/41/6 67/27/6 –
Tibial 98/2/0 80/18/2 75/23/2 84/16/0
Sural – 47/45/8 55/37/8 –
Table 2 Correlation of the three outcome variables of MRC sum
score, ODSS score, diagnosis of critical illness polyneuropathy
(= CIP) with the independent variables age of the patient, time from
ICU discharge to follow-up, APACHE score, days of treatment on
ICU, and days of ventilator support
MRC sum score ODSS CIP
Gender (male) p = 0.07 p = 0.22 p = 0.43
Age (years) r = -0.04; p = 0.80 r = 0.03; p = 0.84 p = 0.43
ICU discharge (months) r = -0.41; p = 0.77 r = 0.76; p = 0.60 p = 0.08
Sepsis p = 0.87 p = 0.32 p = 0.52
APACHE II score r = -0.33; p = 0.021 r = 0.31; p = 0.029 p = 0.065
ICU treatment (days) r = -0.27; p = 0.053 r = 0.39; p = 0.004 p = 0.015
Ventilator support (days) r = -0.33; p = 0.017 r = 0.47; p \ 0.001 p = 0.006
The Spearman rank correlation coefficient (r) and the corresponding p levels are shown. In case of binary variables (gender, diagnosis of sepsis,
diagnosis of critical illness polyneuropathy (= CIP)), the Mann–Whitney test was applied. Direct comparison of two binary variables was done
with Fisher’s exact test
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diseases, relatively young age, and rehabilitation), the
long-term prognosis of ICU-acquired weakness is
favorable.
CIP could be diagnosed in 41 % of patients. It is very
unlikely that the clinical signs and symptoms and the
abnormalities in the nerve conduction found in these
patients were attributable to other causes than CIP, as only
selected patients with normal laboratory results were
included in the study. The abnormalities in nerve conduc-
tion studies were moderate and were not accompanied by a
disabling reduction of arm and leg function as expressed in
a low ODSS score in those patients diagnosed with CIP.
The ODSS score for all ICU survivors including those
without nerve conduction abnormalities was very low
indicating minor symptoms in the arms or in walking
without affection of daily activities.
Accordingly, the median MRC sum score of 60 in all ICU
survivors suggests that a thorough neurological examination
could reveal minimal muscular weakness in the majority of
patients. Twenty-nine of 51 patients (57 %) showed no
muscular weakness at all (MRC sum score of 60). MRC sum
scores were lower in patients diagnosed with CIP, while
patients without CIP showed no muscle weakness.
Differentiating CIP from CIM can be difficult clinically
during ICU treatment and often both syndromes occur at
the same time causing ICU-acquired muscular weakness.
Nerve conduction studies can be helpful to differentiate
CIP from CIM. Especially the depression or absence of
sensible nerve action potentials (SNAP) amplitudes is a
strong indicator of CIP, since SNAPs are normal in pure
myopathic disease. All patients diagnosed with CIP had
abnormalities in sensory nerve conduction studies. When
the presence of additional CIM could not be excluded on
basis of clinical examination and nerve conduction studies,
we performed EMG that showed neurogenic changes in all
examined muscles. This means that in our study sample,
there was no patient with muscular weakness that was only
or mainly attributable to CIM, indicating that CIM has a
more favorable prognosis than CIP. This is well in line with
previous reports, where CIP was the main diagnosis asso-
ciated with persistent disability, while CIM is often asso-
ciated with a more rapid and complete recovery [8, 16].
Prospective trials have shown that the development of
ICU-acquired muscular weakness is associated with the
severity of illness as measured by severity of illness scores,
the presence of sepsis or SIRS, duration of ICU stay, and
the duration of mechanical ventilation [7, 11]. In part, this
is also the case for the long-term outcome of ICU-acquired
muscular weakness. MRC score, ODSS score, and diag-
nosis of CIP are correlated with the risk factors APACHE
Score, duration of ICU treatment, and duration of ventilator
support. It is surprising, however, that the diagnosis of
sepsis, which is a very important risk factor for the
development of ICU-acquired muscular weakness during
ICU stay, does not impair the long-term neuromuscular
outcome of ICU survivors. Although sepsis leads to an
extension of ICU treatment and duration of ventilator
support, the diagnosis of sepsis does not constitute an
additional independent risk factor.
The most important predictor of long-term neuromus-
cular outcome was the duration of ventilator support.
Speculatively, the duration of neuromuscular inactivity
induced by the analgo-sedation necessary for ventilator
support is important for this correlation, but inactivation
was reported to lead to loss of muscle bulk and not
development of neuropathy [20]. Therefore, the underlying
disease that led to a long duration of ventilator support and
muscular inactivation may be more important in your study
population than prolonged bed rest itself. Age and gender
do not predict the long-term neuromuscular outcome of
critical illness.
Taken together, this study indicates that the long-term
prevalence and severity of ICU-AW is slight 6–24 months
after ICU treatment in relatively young patients with no
concomitant diseases. Even patients in the highest quartile
of duration of ventilator support still show an acceptable
outcome (mean MRC score 56.93 and mean ODSS score of
2.14). Although ICU-acquired muscular weakness is a
serious complication of ICU treatment, this should not
influence therapeutic decisions, given its possible favorable
long-term prognosis even in the presence of risk factors
such as high APACHE score, long duration of ICU treat-
ment, or long duration of ventilator support and patients
and their relatives should be advised accordingly.
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